HeyJaredCommunity Health Media
Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns.
- Indexed episodes, last 90 days
- 8
- Latest publication
- Sep 29, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 7, 2026
Latest episodes
Navigating First-Line CLL Treatment with Drs. Kerry Rogers, William Wierda & Catherine Coombs (opens the original)
Read excerpt
With more targeted therapies available for CLL, how are clinicians navigating the growing number of first-line treatment options? Drs. Kerry Rogers, William Wierda, and Catherine Coombs discuss the evolving CLL treatment landscape, including fixed-duration versus continuous therapy, BTK- and BCL-2 inhibitor–based approaches, and how disease biology, comorbidities, treatment logistics, and patient preferences can guide treatment selection. Topics discussed: Fixed-duration vs. continuous first-lin
Evolving First-Line HER2+ Metastatic Breast Cancer with Drs. Sonya Reid & Shruti Singh (opens the original)
Read excerpt
For more than a decade, THP—established by the landmark CLEOPATRA trial— defined the first-line standard for HER2-positive metastatic breast cancer. Now, DESTINY-Breast09 is changing the conversation. In this CHM Conversation , Dr. Sonya Reid and Dr. Shruti Singh discuss the evolving first-line treatment landscape and how trastuzumab deruxtecan (T-DXd) plus pertuzumab is reshaping clinical decision-making for patients with HER2-positive metastatic breast cancer. They explore which patients may b
This Moment in Medicine: First-Line ADCs in Metastatic TNBC with Dr. Senthil Damodaran (opens the original)
Read excerpt
Are antibody-drug conjugates becoming the new first-line standard for metastatic triple-negative breast cancer? At This Moment in Medicine, hosted by Community Health Media, Dr. Senthil Damodaran reviews the latest data moving ADCs earlier in the treatment landscape for metastatic TNBC. The presentation focuses on TROPION-Breast02, ASCENT-03, and ASCENT-04, comparing datopotamab deruxtecan (Dato-DXd) and sacituzumab govitecan with chemotherapy, with or without pembrolizumab depending on PD-L1 st
This Moment In Medicine: First-Line HER2+ Metastatic Breast Cancer with Dr. Mothaffar Rimawi (opens the original)
Read excerpt
How should we approach first-line treatment as the HER2-positive metastatic breast cancer landscape rapidly evolves? At This Moment in Medicine, hosted by Community Health Media, Dr. Mothaffar Rimawi examines how new data are reshaping a treatment landscape long defined by the CLEOPATRA regimen. From DESTINY-Breast09 to PATINA and HER2CLIMB-05, Dr. Rimawi explores emerging strategies for deeper HER2 and ER pathway inhibition, the role of T-DXd, and how clinicians might individualize treatment ba
This Moment in Medicine: T-DXd in Early HER2+ BC with Dr. Michelina Cairo (opens the original)
Read excerpt
Where should T-DXd fit in the treatment of high-risk, early-stage HER2-positive breast cancer? At This Moment in Medicine, hosted by Community Health Media, Dr. Michelina Cairo reviews the latest data from DESTINY-Breast11 and DESTINY-Breast05, examining how trastuzumab deruxtecan (T-DXd) could reshape treatment in both the neoadjuvant and adjuvant settings. From pathologic complete response and invasive disease-free survival to ILD risk and treatment sequencing, the presentation explores how cl
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Not enough subject data for this period yet.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.